SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA's approval for Divalproex Sodium ER Tablets USP

22 Oct 2019 Evaluate

Lupin has received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Depakote Extended-Release Tablets, 250 mg and 500 mg, of AbbVie Inc.

Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg (RLD: Depakote ER) had annual sales of approximately $159 million in the U.S. (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2506.70 49.25 (2.00%)
09-Jul-2026 13:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.40
Dr. Reddys Labs. 1270.30
Cipla 1446.90
Zydus Lifesciences 1159.75
Lupin 2506.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: